COCRYSTAL PHARMA NEW O.N. (F:8CC) — Market Cap & Net Worth
Market Cap & Net Worth: COCRYSTAL PHARMA NEW O.N. (8CC)
COCRYSTAL PHARMA NEW O.N. (F:8CC) has a market capitalization of $11.12 Million (€9.51 Million) as of August 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #26768 globally and #2296 in its home market, demonstrating a -12.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying COCRYSTAL PHARMA NEW O.N.'s stock price €0.69 by its total outstanding shares 13785759 (13.79 Million). Review COCRYSTAL PHARMA NEW O.N. balance sheet liabilities to assess the company's total debt and financial obligations.
COCRYSTAL PHARMA NEW O.N. Market Cap History: 2020 to 2026
COCRYSTAL PHARMA NEW O.N.'s market capitalization history from 2020 to 2026. Data shows change from $220.48 Million to $11.12 Million (-34.78% CAGR).
COCRYSTAL PHARMA NEW O.N. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how COCRYSTAL PHARMA NEW O.N.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 8CC by Market Capitalization
Companies near COCRYSTAL PHARMA NEW O.N. in the global market cap rankings as of August 5, 2026.
Key companies related to COCRYSTAL PHARMA NEW O.N. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
COCRYSTAL PHARMA NEW O.N. Historical Marketcap From 2020 to 2026
Between 2020 and today, COCRYSTAL PHARMA NEW O.N.'s market cap moved from $220.48 Million to $ 11.12 Million, with a yearly change of -34.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €11.12 Million | -14.29% |
| 2025 | €12.97 Million | -72.24% |
| 2024 | €46.74 Million | +87.10% |
| 2023 | €24.98 Million | -9.88% |
| 2022 | €27.72 Million | -74.40% |
| 2021 | €108.31 Million | -50.88% |
| 2020 | €220.48 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of COCRYSTAL PHARMA NEW O.N. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.12 Million USD |
| MoneyControl | $11.12 Million USD |
| MarketWatch | $11.12 Million USD |
| marketcap.company | $11.12 Million USD |
| Reuters | $11.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About COCRYSTAL PHARMA NEW O.N.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hep… Read more